Details of the Drug

General Information of Drug (ID: DM7MT6E)

Drug Name

Prasugrel

Synonyms

Effient (TN)

Indication

Disease Entry	ICD 11	Status	REF
Acute coronary syndrome	BA41	Approved	[1]
------------------------------------------------------------------------------------

Affected Organisms

Humans and other mammals

ATC Code

B01AC22: Prasugrel

B01AC: Platelet aggregation inhibitors excl. heparin

B01A: ANTITHROMBOTIC AGENTS

B01: ANTITHROMBOTIC AGENTS

B: BLOOD AND BLOOD FORMING ORGANS

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

373.4

Logarithm of the Partition Coefficient (xlogp)

3.6

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Elimination: 1% of drug is excreted from urine in the unchanged form [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 7.4 hours [3]
Metabolism: The drug is metabolized via the human carboxylesterase (hCE) 2 []
Vd: The volume of distribution (Vd) of drug is 44-68 L []

Chemical Identifiers

Formula: C20H20FNO3S
IUPAC Name: [5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-6,7-dihydro-4H-thieno[3,2-c]pyridin-2-yl] acetate
Canonical SMILES: CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4
InChI: InChI=1S/C20H20FNO3S/c1-12(23)25-18-10-14-11-22(9-8-17(14)26-18)19(20(24)13-6-7-13)15-4-2-3-5-16(15)21/h2-5,10,13,19H,6-9,11H2,1H3
InChIKey: DTGLZDAWLRGWQN-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 6918456
ChEBI ID: CHEBI:87723
CAS Number: 150322-43-3
UNII: 34K66TBT99
DrugBank ID: DB06209
TTD ID: D07IRF
INTEDE ID: DR1326
ACDINA ID: D00547

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
P2Y purinoceptor 12 (P2RY12)	TTZ1DT0	P2Y12_HUMAN	Inhibitor	[4]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[5]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[5]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[5]
Cytochrome P450 2B6 (CYP2B6)_{Main DME}	DEPKLMQ	CP2B6_HUMAN	Substrate	[5]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Prasugrel

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Vorapaxar	DMA16BR	Major	Increased risk of bleeding by the combination of Prasugrel and Vorapaxar.	Myocardial infarction [BA41-BA43]	[6]
-----------

Coadministration of a Drug Treating the Disease Different from Prasugrel (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Oliceridine	DM6MDCF	Moderate	Altered absorption of Prasugrel due to GI dynamics variation caused by Oliceridine.	Acute pain [MG31]	[7]
Levomilnacipran	DMV26S8	Moderate	Increased risk of bleeding by the combination of Prasugrel and Levomilnacipran.	Chronic pain [MG30]	[8]
Regorafenib	DMHSY1I	Major	Increased risk of bleeding by the combination of Prasugrel and Regorafenib.	Colorectal cancer [2B91]	[9]
Intedanib	DMSTA36	Moderate	Increased risk of bleeding by the combination of Prasugrel and Intedanib.	Colorectal cancer [2B91]	[10]
Ardeparin	DMYRX8B	Major	Increased risk of bleeding by the combination of Prasugrel and Ardeparin.	Coronary thrombosis [BA43]	[11]
Danaparoid	DM6CLBN	Major	Increased risk of bleeding by the combination of Prasugrel and Danaparoid.	Deep vein thrombosis [BD71]	[11]
Rivaroxaban	DMQMBZ1	Major	Increased risk of bleeding by the combination of Prasugrel and Rivaroxaban.	Deep vein thrombosis [BD71]	[12]
Vilazodone	DM4LECQ	Moderate	Increased risk of bleeding by the combination of Prasugrel and Vilazodone.	Depression [6A70-6A7Z]	[8]
Vortioxetine	DM6F1PU	Moderate	Increased risk of bleeding by the combination of Prasugrel and Vortioxetine.	Depression [6A70-6A7Z]	[8]
Desvenlafaxine	DMHD4PE	Moderate	Increased risk of bleeding by the combination of Prasugrel and Desvenlafaxine.	Depression [6A70-6A7Z]	[8]
Apigenin	DMI3491	Minor	Increased risk of bleeding by the combination of Prasugrel and Apigenin.	Discovery agent [N.A.]	[13]
Tazemetostat	DMWP1BH	Major	Increased risk of bleeding by the combination of Prasugrel and Tazemetostat.	Follicular lymphoma [2A80]	[9]
Avapritinib	DMK2GZX	Major	Increased risk of bleeding by the combination of Prasugrel and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[9]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of bleeding by the combination of Prasugrel and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[14]
Acalabrutinib	DM7GCVW	Major	Increased risk of bleeding by the combination of Prasugrel and Acalabrutinib.	Mature B-cell lymphoma [2A85]	[15]
Ibrutinib	DMHZCPO	Major	Increased risk of bleeding by the combination of Prasugrel and Ibrutinib.	Mature B-cell lymphoma [2A85]	[7]
Ponatinib	DMYGJQO	Major	Increased risk of bleeding by the combination of Prasugrel and Ponatinib.	Mature B-cell lymphoma [2A85]	[16]
Panobinostat	DM58WKG	Major	Increased risk of bleeding by the combination of Prasugrel and Panobinostat.	Multiple myeloma [2A83]	[17]
Fedratinib	DM4ZBK6	Major	Increased risk of bleeding by the combination of Prasugrel and Fedratinib.	Myeloproliferative neoplasm [2A20]	[9]
Ruxolitinib	DM7Q98D	Major	Increased risk of bleeding by the combination of Prasugrel and Ruxolitinib.	Myeloproliferative neoplasm [2A20]	[9]
Nepafenac	DMYK490	Moderate	Increased risk of bleeding by the combination of Prasugrel and Nepafenac.	Osteoarthritis [FA00-FA05]	[18]
MK-4827	DMLYGH4	Moderate	Increased risk of bleeding by the combination of Prasugrel and MK-4827.	Ovarian cancer [2C73]	[9]
Choline salicylate	DM8P137	Moderate	Increased risk of bleeding by the combination of Prasugrel and Choline salicylate.	Postoperative inflammation [1A00-CA43]	[19]
Curcumin	DMQPH29	Minor	Increased risk of bleeding by the combination of Prasugrel and Curcumin.	Solid tumour/cancer [2A00-2F9Z]	[20]
Plicamycin	DM7C8YV	Major	Increased risk of bleeding by the combination of Prasugrel and Plicamycin.	Testicular cancer [2C80]	[9]
Apixaban	DM89JLN	Major	Increased risk of bleeding by the combination of Prasugrel and Apixaban.	Thrombosis [DB61-GB90]	[9]
Brilinta	DMBR01X	Moderate	Increased risk of bleeding by the combination of Prasugrel and Brilinta.	Thrombosis [DB61-GB90]	[9]
Cabozantinib	DMIYDT4	Major	Increased risk of bleeding by the combination of Prasugrel and Cabozantinib.	Thyroid cancer [2D10]	[21]
Betrixaban	DM2C4RF	Major	Increased risk of bleeding by the combination of Prasugrel and Betrixaban.	Venous thromboembolism [BD72]	[22]
-----------


⏷ Show the Full List of 29 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sucrose stearate	E00502	9898327	Dispersing agent; Emulsifying agent; Modified-release agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium	E00625	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Glyceryl behenate	E00481	5362585	Binding agent; Coating agent; Flavoring agent; Modified-release agent; Viscosity-controlling agent; lubricant
Glyceryl dibehenate	E00537	22477175	Binding agent; Coating agent; Flavoring agent; Modified-release agent; Viscosity-controlling agent; lubricant
Hydroxypropyl cellulose	E00632	Not Available	Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Haematite red	E00236	14833	Colorant
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent
--------------------


⏷ Show the Full List of 19 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Prasugrel 10 mg tablet	10 mg	Oral Tablet	Oral
Prasugrel 5 mg tablet	5 mg	Oral Tablet	Oral
Prasugrel Hydrochloride eq 10mg base tablet	eq 10mg base	Tablet	Oral
Prasugrel Hydrochloride eq 5mg base tablet	eq 5mg base	Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7562).
2	BDDCS applied to over 900 drugs
3	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
5	The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs. 2012 Nov 12;72(16):2087-116.
6	Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
7	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
8	Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
9	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
10	Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
11	Price AJ, Frcpath DO "Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?" Ann R Coll Surg Engl 77 (1995): 395. [PMID: 7486773]
12	Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
13	Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7 quiz 1228-30. [PMID: 10902065]
14	Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
15	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
16	Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
17	Cerner Multum, Inc. "Australian Product Information.".
18	Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
19	Product Information. Effient (prasugrel). Lilly, Eli and Company, Indianapolis, IN.
20	Abebe W "Herbal medication: potential for adverse interactions with analgesic drugs." J Clin Pharm Ther 27 (2002): 391-401. [PMID: 12472978]
21	Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
22	Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.